Core Insights - Alnylam Pharmaceuticals reported a significant decline in revenue for Q3 2024, with total revenue of $500.92 million, down 33.3% year-over-year, and an EPS of -$0.50 compared to $1.15 a year ago [1] - The reported revenue fell short of the Zacks Consensus Estimate of $529.34 million, resulting in a surprise of -5.37% [1] Revenue Performance - Net Product Revenue for Oxlumo in the U.S. was $14.93 million, slightly below the average estimate of $15.73 million, but showed a year-over-year increase of 53.7% [3] - Net Product Revenue for Amvuttra in the U.S. reached $168.66 million, exceeding the average estimate of $153.83 million, with a year-over-year growth of 48.6% [3] - Net Product Revenue for Givlaari in the U.S. was $40.37 million, below the average estimate of $42.96 million, but still represented a 9.1% increase year-over-year [3] - Net Product Revenue for Onpattro in the U.S. was $16.21 million, below the average estimate of $18.23 million, reflecting a year-over-year decline of 25.9% [3] - Total net product revenues amounted to $420.15 million, surpassing the 10-analyst average estimate of $414.11 million, with a year-over-year increase of 34.2% [3] - Royalty revenue was reported at $23.39 million, exceeding the average estimate of $22.32 million, marking a significant year-over-year increase of 136.1% [3] - Net revenues from research collaborators were $57.39 million, falling short of the average estimate of $96.03 million [3] Stock Performance - Alnylam's shares have returned +3.7% over the past month, outperforming the Zacks S&P 500 composite, which saw a +1% change [4] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [4]

Alnylam Pharmaceuticals (ALNY) came out with a quarterly loss of $0.50 per share in line with the Zacks Consensus Estimate. This compares to earnings of $1.15 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this RNA interference drug developer would post a loss of $0.74 per share when it actually produced earnings of $0.56, delivering a surprise of 175.68%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.A ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________ FORM 10-Q ____________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, $0.01 par value per share ALNY The Nasdaq Stock Market LLC For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 O ...

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, with the aim of buying high and selling higher, leveraging established price movements for profitable trades [1]. Company Overview: Alnylam Pharmaceuticals (ALNY) - Alnylam Pharmaceuticals currently holds a Momentum Style Score of A, indicating strong momentum characteristics [1]. - The company has a Zacks Rank of 2 (Buy), suggesting a favorable outlook based on historical performance metrics [2]. Performance Metrics - Over the past week, ALNY shares increased by 4.08%, outperforming the Zacks Medical - Biomedical and Genetics industry, which rose by 2.24% [3]. - In the last month, ALNY's price change was 9.4%, significantly higher than the industry's 1.44% [3]. - Over the past quarter, ALNY shares have risen by 26.8%, and they have increased by 80.82% over the last year, compared to the S&P 500's gains of 5.5% and 40.28%, respectively [3]. Trading Volume - ALNY's average 20-day trading volume is 740,644 shares, which serves as a bullish indicator when combined with rising stock prices [3]. Earnings Outlook - In the last two months, one earnings estimate for ALNY has increased while one has decreased, leading to a consensus estimate improvement from -$0.83 to -$0.64 [4]. - For the next fiscal year, one estimate has moved upwards, while three have been revised downwards [4]. Conclusion - Given the strong performance metrics and positive earnings outlook, ALNY is positioned as a solid momentum pick with a Momentum Score of A and a Zacks Rank of 2 (Buy) [4].

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Alnylam Pharmaceuticals (ALNY) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out. Alnylam Pharmaceuticals is one of 1025 companies in the Medical group. The Medical group currently sits at #1 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks ...

Core Viewpoint - Alnylam Pharmaceuticals has submitted a Type II Variation to the European Medicines Agency for vutrisiran, aimed at treating ATTR amyloidosis with cardiomyopathy, which has positively impacted its stock price [1] Group 1: Company Developments - Vutrisiran is already marketed in the EU under the brand name Amvuttra for hereditary transthyretin-mediated amyloidosis [1] - The application for vutrisiran to treat ATTR-CM is backed by positive results from the HELIOS-B study, which met all primary and secondary endpoints with statistical significance [1][2] - Year-to-date, Alnylam's shares have increased by 57%, contrasting with a 1% decline in the industry [2] Group 2: Product Performance - Amvuttra generated sales of $425.4 million in the first half of 2024, reflecting an 82% year-over-year increase [3] - The growth in Amvuttra sales is attributed to new patient initiations and patients switching from Onpattro [3] - If approved, vutrisiran could become the new standard of care for ATTR-CM, significantly expanding the eligible patient population [4] Group 3: Other Products and Collaborations - Alnylam also markets Givlaari and Oxlumo for other conditions, contributing to its revenue [4] - The company collaborates with Novartis for Leqvio, which is approved for hypercholesterolemia treatment in the EU and the U.S. [5]

Alnylam Pharmaceuticals (ALNY) focuses on developing novel therapeutics based on RNAi technology. The company’s pipeline of experimental RNAi therapeutics is focused on three strategic therapeutic areas — genetic medicines, cardio-metabolic disease and hepatic infectious disease. Alnylam’s marketed portfolio of drugs comprises Amvuttra (vutrisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Onpattro (patisiran).Let’s delve deeper to discuss four reasons why adding Alnylam stock to your portfolio may prov ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Alnylam Pharmaceuticals (ALNY) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. Alnylam Pharmaceuticals is one of 1026 individual stocks in the Medical sector. Colle ...

Alnylam Pharmaceuticals NASDAQ: ALNY stock price action has been volatile but is uptrending and has gained 100% in the last two years. The uptrend is driven by increasing expectations for market-disrupting heart treatment and could double the price again. The latest action has the market up more than 65% in the last two months and heading to the $350 to $415 range based on the technicals. Alnylam Pharmaceuticals TodayALNYAlnylam Pharmaceuticals$261.91 +5.70 (+2.22%) 52-Week Range$141.98▼$287.55Price Target$ ...

Core Viewpoint - Alnylam Pharmaceuticals' shares fell 8.5% following the announcement of detailed data from the phase III HELIOS-B study for its investigational RNAi therapeutic, Amvuttra, aimed at treating transthyretin-mediated amyloidosis with cardiomyopathy [1][2]. Group 1: Study Results - The HELIOS-B study met its primary endpoint, showing a statistically significant reduction in all-cause mortality and recurrent cardiovascular events in both the overall and monotherapy populations [1]. - Treatment with vutrisiran resulted in a 30% reduction in mortality in the monotherapy population during the double-blind period, but this reduction was deemed non-significant by management [1]. Group 2: Market Performance - Alnylam's shares have increased by 37.3% year-to-date, significantly outperforming the industry growth of 0.6% [4]. - The company reported sales of $425.4 million for Amvuttra in the first half of 2024, reflecting an 82% year-over-year increase [6]. Group 3: Regulatory and Future Prospects - Alnylam plans to submit a supplemental new drug application for vutrisiran to the FDA using a Priority Review Voucher later in 2024 [5]. - If approved for the new indication, vutrisiran is expected to become the new standard of care for treating ATTR amyloidosis with cardiomyopathy, potentially increasing sales and expanding the patient population [6].